RxDoctor Payments DataLook up a doctor →

Amy Hite, MD

Internal Medicine · Akron, OHNPI 1790881019

Payments from drug & device makers

$304,830in general payments, 2019–2025

Across 659 payments — averaging $462.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Gilead$205K
  • Viiv Healthcare Company$39K
  • Janssen Products, LP$34K
  • GSK$22K
  • Theratechnologies Inc.$3K
  • Johnson & Johnson$898
  • plus $960 from 4 others

What the payments were for

  • Consulting fees$26,86511%
  • Speaking & faculty fees$202,15980%
  • Travel & lodging$10,4244%
  • Food & beverage$13,1265%
  • Education$1420%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$304,830 in reported general payments places this provider in the 95th percentile of 4,428 internal medicine providers in Ohio.

See all internal medicine providers in Ohio

Medicare billing

Part B allowed, 2024
$4,981
Medicare patients
19
Services billed
49

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BiktarvyBictegrav/Emtricit/Tenofov Ala417$1,644,443
GenvoyaElviteg/Cob/Emtri/Tenof Alafen157$623,756
TriumeqAbacavir/Dolutegravir/Lamivudi92$348,012
RukobiaFostemsavir Tromethamine21$185,755
JulucaDolutegravir/Rilpivirine34$114,001
TivicayDolutegravir Sodium41$112,644
PrezcobixDarunavir/Cobicistat36$88,588
SymtuzaDarunavir/Cob/Emtri/Tenof Alaf16$73,070
PifeltroDoravirine40$69,473
OdefseyEmtricitab/Rilpiviri/Tenof Ala17$66,219
DescovyEmtricitabine/Tenofov Alafenam22$47,289
Isentress HdRaltegravir Potassium20$38,977
MytesiCrofelemer11$37,980
Darunavir38$22,694
VemlidyTenofovir Alafenamide11$18,458

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GileadBiktarvy, Genvoya, Descovy, Vemlidy$205,438$2,333,946607 claims
Viiv Healthcare CompanyTriumeq, Rukobia, Juluca, Tivicay$38,902$760,413188 claims
MerckPifeltro, Isentress Hd$755$108,44960 claims
Johnson & JohnsonPrezcobix$898$88,58836 claims
Janssen Products, LPSymtuza$33,547$73,07016 claims
Napo Pharmaceuticals IncMytesi$128$37,98011 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,428 internal medicine providers in Ohio.

Other internal medicine in Akron

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →